33.16

0.39% -0.13

Alkermes Plc (ALKS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ALKS? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$33.29

Offen:

$33.52

24-Stunden-Volumen:

989.05K

Relative Volume:

0.48

Marktkapitalisierung:

$5.48B

Einnahmen:

$1.51B

Nettoeinkommen (Verlust:

$333.35M

KGV:

17.01

EPS:

1.95

Netto-Cashflow:

$315.22M

1W Leistung:

-5.01%

1M Leistung:

+13.76%

6M Leistung:

+15.82%

1J Leistung:

-7.89%

1-Tages-Spanne:

$33.09

$34.27

1-Wochen-Bereich:

$33.04

$35.34

52-Wochen-Spanne:

$25.16

$36.45

Alkermes Plc Stock (ALKS) Company Profile

Firmenname

Alkermes Plc

Sektor

Healthcare (1111)

Branche

Drug Manufacturers - Specialty & Generic (83)

Telefon

00-353-1-772-8000

Adresse

CONNAUGHT HOUSE, DUBLIN 4

Mitarbeiter

1,800

Twitter

@alkermes

Nächster Verdiensttermin

2024-10-24

Neueste SEC-Einreichungen

ALKS's Discussions on Twitter

Compare ALKS vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALKS Alkermes Plc	33.16	5.50B	1.51B	333.35M	315.22M	1.95
TAK Takeda Pharmaceutical Co Adr	18.46	58.03B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	126.65	55.37B	9.40B	2.65B	2.24B	5.935
HLN Haleon Plc Adr	11.20	49.70B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	33.98	39.50B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	473.66	20.50B	3.13B	1.27B	1.12B	26.39

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-11	Eingeleitet	Truist	Buy
2025-09-26	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2025-09-03	Eingeleitet	Wells Fargo	Overweight
2025-07-15	Eingeleitet	Goldman	Buy
2025-06-17	Hochstufung	UBS	Neutral → Buy
2025-05-28	Eingeleitet	Needham	Buy
2025-03-13	Eingeleitet	RBC Capital Mkts	Sector Perform
2025-03-04	Hochstufung	UBS	Sell → Neutral
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-11-05	Hochstufung	Stifel	Hold → Buy
2024-06-17	Eingeleitet	TD Cowen	Buy
2024-03-19	Eingeleitet	Robert W. Baird	Outperform
2024-02-20	Herabstufung	UBS	Neutral → Sell
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-10-24	Hochstufung	Evercore ISI	In-line → Outperform
2023-10-17	Eingeleitet	UBS	Neutral
2022-11-03	Hochstufung	Piper Sandler	Neutral → Overweight
2022-10-14	Hochstufung	BofA Securities	Underperform → Neutral
2022-08-16	Eingeleitet	Piper Sandler	Neutral
2022-04-22	Fortgesetzt	Goldman	Buy
2022-04-20	Eingeleitet	Goldman	Buy
2022-01-27	Hochstufung	Cantor Fitzgerald	Hold → Overweight
2021-12-01	Eingeleitet	Citigroup	Neutral
2021-10-07	Hochstufung	Jefferies	Hold → Buy
2021-09-02	Herabstufung	BofA Securities	Neutral → Underperform
2020-10-15	Hochstufung	Mizuho	Neutral → Buy
2020-07-30	Herabstufung	Goldman	Neutral → Sell
2020-02-14	Herabstufung	BofA/Merrill	Buy → Neutral
2020-02-14	Bestätigt	H.C. Wainwright	Neutral
2020-02-14	Herabstufung	JP Morgan	Overweight → Neutral
2020-02-06	Eingeleitet	Mizuho	Neutral
2020-01-31	Hochstufung	Wolfe Research	Underperform → Peer Perform
2019-09-05	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2019-07-15	Hochstufung	Goldman	Sell → Neutral
2019-05-31	Eingeleitet	H.C. Wainwright	Neutral
2019-05-01	Herabstufung	Citigroup	Buy → Neutral
2018-12-19	Herabstufung	Goldman	Neutral → Sell
2018-12-14	Eingeleitet	Wolfe Research	Underperform
2018-12-13	Herabstufung	Credit Suisse	Outperform → Underperform
2018-11-05	Eingeleitet	Piper Jaffray	Neutral
2018-08-07	Eingeleitet	Stifel	Hold
2018-06-21	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2018-06-06	Eingeleitet	B. Riley FBR, Inc.	Buy
2018-05-16	Hochstufung	Citigroup	Neutral → Buy
2018-05-11	Eingeleitet	BofA/Merrill	Buy

Alle ansehen

Alkermes Plc Aktie (ALKS) Neueste Nachrichten

06:04 AM

Public Sector Pension Investment Board Has $21.32 Million Stock Holdings in Alkermes plc $ALKS - MarketBeat

06:04 AM

Feb 13, 2026

Is Alkermes plc a top pick in the sectorCEO Change & Weekly Stock Performance Updates - mfd.ru

Feb 13, 2026

Alkermes Completes $2.1 Billion Acquisition of Avadel Pharmaceuticals - CHEManager

Feb 13, 2026

Feb 12, 2026

Alkermes plc completes acquisition of Avadel Pharmaceuticals plc, accelerating entry into sleep medicine market - marketscreener.com

Feb 12, 2026

MDGL Strengthens MASH Franchise With New Genetic Approaches - Finviz

Feb 12, 2026

Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market - BioSpace

Feb 12, 2026

Alkermes PLC Completes Acquisition Of Avadel Pharmaceuticals PLC, Accelerating Entry Into Sleep Medicine Market - TradingView

Feb 12, 2026

Alkermes PLC has successfully completed the acquisition of Avadel Pharmaceuticals plc. - Bitget

Feb 12, 2026

Alkermes Acquires Avadel Pharmaceuticals - Contract Pharma

Feb 12, 2026

Alkermes, Inc. , Alkermes, Inc and Alkermes Finance LLC Enters into Credit Agreement - marketscreener.com

Feb 12, 2026

Alkermes Completes Acquisition and Delisting of Avadel Pharmaceuticals - TipRanks

Feb 12, 2026

Alkermes Acquires Avadel to Expand Product Portfolio - Intellectia AI

Feb 12, 2026

Avadel Pharmaceuticals Terminates Multiple Agreements Following Alkermes Acquisition - TradingView

Feb 12, 2026

Alkermes (Nasdaq: ALKS) closes Avadel acquisition, adds LUMRYZ and $1.5B loans - Stock Titan

Feb 12, 2026

Alkermes Completes Acquisition of Avadel Pharmaceuticals, Adding LUMRYZ to Portfolio - Sleep Review

Feb 12, 2026

Feb 11, 2026

Understanding the Setup: (ALKS) and Scalable Risk - Stock Traders Daily

Feb 11, 2026

Alkermes to report fourth quarter and year-end financial results on Feb. 25, 2026 - MSN

Feb 11, 2026

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 - Business Wire

Feb 11, 2026

Alkermes earnings up next as sleep strategy takes shape - Investing.com

Feb 11, 2026

Can Alkermes plc stock surprise with earnings upsideEarnings Growth Summary & Stock Portfolio Risk Management - mfd.ru

Feb 11, 2026

Feb 10, 2026

Irish High Court sanctions Avadel Pharmaceuticals acquisition by Alkermes - TipRanks

Feb 10, 2026

Alkermes (ALKS) Set to Finalize Acquisition of Avadel Pharmaceuticals - GuruFocus

Feb 10, 2026

Avadel Pharmaceuticals plc Announces High Court Approval of Scheme of Arrangement for Acquisition by Alkermes plc - Quiver Quantitative

Feb 10, 2026

Avadel Pharmaceuticals Announces Outcome of the Court Sanction Hearing - The Manila Times

Feb 10, 2026

Irish court clears Alkermes buyout; Avadel stock trading ends Feb. 11 - Stock Titan

Feb 10, 2026

Alkermes Increases Offer for Avadel Acquisition - MSN

Feb 10, 2026

INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales - Finviz

Feb 10, 2026

Feb 09, 2026

IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus - Finviz

Feb 09, 2026

Alkermes plc (NASDAQ:ALKS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Feb 09, 2026

Feb 08, 2026

History Review: Will Alkermes plc outperform its industry peersJuly 2025 Selloffs & AI Powered Market Entry Ideas - baoquankhu1.vn

Feb 08, 2026

Allianz Asset Management GmbH Acquires 511,702 Shares of Alkermes plc $ALKS - MarketBeat

Feb 08, 2026

Feb 06, 2026

KOD Stock Up 24% in 3 Months: Here's What You Need to Know - Finviz

Feb 06, 2026

Feb 05, 2026

Stop Loss: Is Alkermes plc benefiting from interest rate changesPrice Action & Community Trade Idea Sharing Platform - baoquankhu1.vn

Feb 05, 2026

Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz

Feb 05, 2026

Feb 04, 2026

Alkermes (ALKS) Projected to Post Earnings on Wednesday - MarketBeat

Feb 04, 2026

Feb 03, 2026

Here's Why Gilead Sciences Stock Surged 21% in a Month - Finviz

Feb 03, 2026

Feb 02, 2026

Alkermes (NASDAQ:ALKS) Director Sells $2,115,684.00 in Stock - MarketBeat

Feb 02, 2026

Alkermes (NASDAQ:ALKS) EVP Craig Hopkinson Sells 9,000 Shares - MarketBeat

Feb 02, 2026